Cargando…

Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours

BACKGROUND: Dulanermin (rhApo2L/TRAIL) induces apoptosis by binding to death receptors DR4 and DR5, leading to caspase activation and subsequent cell death. A Phase1a trial evaluated the safety and tolerability of dulanermin in patients with advanced tumours. One aim was to develop and validate phar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Y, Xu, R, Peach, M, Huang, C-P, Branstetter, D, Novotny, W, Herbst, R S, Eckhardt, S G, Holland, P M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251880/ https://www.ncbi.nlm.nih.gov/pubmed/22033270 http://dx.doi.org/10.1038/bjc.2011.456

Ejemplares similares

Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin)
por: Singh, Kamini, et al.
Publicado: (2014)

TRAIL Deficiency Contributes to Diabetic Nephropathy in Fat-Fed ApoE(-/-) Mice
por: Cartland, Siân P., et al.
Publicado: (2014)

Targeting AML through DR4 with a novel variant of rhTRAIL
por: Szegezdi, Eva, et al.
Publicado: (2011)

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
por: Meijer, A, et al.
Publicado: (2013)

Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis
por: Abdulghani, Junaid, et al.
Publicado: (2013)

An added dimension to tumour TRAIL sensitivity
por: Healy, Sandra, et al.
Publicado: (2015)

A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents
por: Arizono, Y, et al.
Publicado: (2003)

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
por: Satterwhite, Julie, et al.
Publicado: (2010)

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL
por: Cheung, Vanessa, et al.
Publicado: (2013)

Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey
por: Zuch de Zafra, Christina L, et al.
Publicado: (2016)

Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children
por: Hathout, Yetrib, et al.
Publicado: (2016)

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis
por: Duiker, E W, et al.
Publicado: (2011)

Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(−/−) mice
por: Knutsson, Anki, et al.
Publicado: (2016)

The interaction between prognostic and pharmacodynamic biomarkers
por: Bouranis, L, et al.
Publicado: (2013)

Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts
por: El-Zawahry, Ahmed, et al.
Publicado: (2005)

Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy
por: Bouralexis, S, et al.
Publicado: (2003)

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma
por: Matthews, G M, et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid
por: Eigenmann, Miro Julian, et al.
Publicado: (2021)

Association between APOE4 and biomarkers in cerebral adrenoleukodystrophy
por: Orchard, Paul J., et al.
Publicado: (2019)

The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice
por: Hylander, Bonnie L, et al.
Publicado: (2005)

Apigenin Sensitizes Prostate Cancer Cells to Apo2L/TRAIL by Targeting Adenine Nucleotide Translocase-2
por: Oishi, Masakatsu, et al.
Publicado: (2013)

A Novel Role of IGF1 in Apo2L/TRAIL-Mediated Apoptosis of Ewing Tumor Cells
por: van Valen, Frans, et al.
Publicado: (2012)

The Organ Trail: A Review of Biomarkers of Organ Failure
por: Dao, Long, et al.
Publicado: (2020)

Pharmacodynamic Modelling of Biomarker Data in Oncology
por: Jackson, Robert C.
Publicado: (2012)

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
por: Greystoke, A, et al.
Publicado: (2011)

IgG-single-chain TRAIL fusion proteins for tumour therapy
por: Siegemund, Martin, et al.
Publicado: (2018)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines
por: Bravo Perina, Lucas, et al.
Publicado: (2023)

APOE as potential biomarkers of moyamoya disease
por: Wu, Haibin, et al.
Publicado: (2023)

Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice
por: Ganai, S, et al.
Publicado: (2009)

Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours
por: Zucali, P A, et al.
Publicado: (2013)

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
por: Razak, A R A, et al.
Publicado: (2011)

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
por: Trivedi, Rachana, et al.
Publicado: (2015)

Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics
por: Kelly, Kaela, et al.
Publicado: (2020)

Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis
por: Marini, Patrizia, et al.
Publicado: (2005)

Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour
por: Shaik Fakiruddin, Kamal, et al.
Publicado: (2018)

Translation of Pharmacodynamic Biomarkers of Antibiotic Efficacy in Specific Populations to Optimize Doses
por: Pai, Manjunath P., et al.
Publicado: (2021)

Model Calibration of Pharmacokinetic-Pharmacodynamic Lung Tumour Dynamics for Anticancer Therapies
por: Ghita, Maria, et al.
Publicado: (2022)

Targeting key pathways in tumour growth and development
por: Herbst, R S
Publicado: (2005)

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gue3tqj939hjdm6bt32bh70ggc